Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOX | P28300 | 17/20 | 0.54 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19274369 | 0.83 | LOX (0.73) | LOXLOXL2MAOA | |
| SCHEMBL12619971 | 0.83 | LOX (0.70) | LOXLOXL2MAOA | |
| SCHEMBL13026629 | 0.83 | LOX (0.50) | LOXLOXL2ALDH1A1CYP3A4MAPK1 | |
| SCHEMBL13067815 | 0.80 | LOX (0.48) | LOXLOXL2ALDH1A1CYP3A4MAPK1 | |
| SCHEMBL9138899 | 0.77 | ALDH1A1 (0.64) | LOXLOXL2ALDH1A1CYP3A4MAPK1 | |
| SCHEMBL19259951 | 0.76 | LOX (0.48) | LOXLOXL2ALDH1A1CYP3A4MAPK1 | |
| SCHEMBL28663727 | 0.75 | LOX (0.47) | LOXLOXL2ALDH1A1CYP3A4MAPK1 | |
| SCHEMBL3005886 | 0.74 | L3MBTL1 (0.43) | LOXLOXL2ALDH1A1MAOAKDM4E | |
| SCHEMBL8624648 | 0.74 | ALDH1A1 (0.67) | ALDH1A1CYP3A4MAPK1KDM4EHPGD | |
| SCHEMBL4328031 | 0.73 | ALDH1A1 (1.00) | ALDH1A1CYP3A4MAPK1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8481696-B2 | Glycosylated glycopeptide antibiotic derivatives | SHIONOGI & CO., LTD. (JP) | 2013-07-09 | — | — | US | disclosed |
| US-20100286364-A1 | GLYCOSYLATED GLYCOPEPTIDE ANTIBIOTIC DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286364-A1 | GLYCOSYLATED GLYCOPEPTIDE ANTIBIOTIC DERIVATIVES | CSGALNACT1, OGT, GALNT1 | LOX 3177/4885LOXL2 4009/4885ALDH1A1 724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.